Chung Y. Kong, Ph.D. - Publications

Affiliations: 
2001 University of Massachusetts, Amherst, Amherst, MA 
Area:
Polymer Chemistry

77 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Hammer MM, Eckel AL, Palazzo LL, Kong CY. Cost-Effectiveness of Treatment Thresholds for Subsolid Pulmonary Nodules in CT Lung Cancer Screening. Radiology. 204418. PMID 34128723 DOI: 10.1148/radiol.2021204418  0.302
2020 Hammer MM, Byrne SC, Kong CY. Factors Influencing the False Positive Rate in CT Lung Cancer Screening. Academic Radiology. PMID 32893112 DOI: 10.1016/J.Acra.2020.07.040  0.381
2020 Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, Mariotto AB, Lowy DR, Feuer EJ. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. The New England Journal of Medicine. 383: 640-649. PMID 32786189 DOI: 10.1056/Nejmoa1916623  0.373
2020 Gupta S, Jacobson FL, Kong CY, Hammer MM. Performance of Lung Nodule Management Algorithms for Lung-RADS Category 4 Lesions. Academic Radiology. PMID 32540198 DOI: 10.1016/J.Acra.2020.04.041  0.336
2020 Criss SD, de Koning HJ, Plevritis SK, Meza R, Kong CY. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. Annals of Internal Medicine. 172: 706-707. PMID 32422089 DOI: 10.7326/L20-0072  0.401
2020 Tramontano AC, Chen Y, Watson TR, Eckel A, Hur C, Kong CY. Racial/ethnic disparities in colorectal cancer treatment utilization and phase-specific costs, 2000-2014. Plos One. 15: e0231599. PMID 32287320 DOI: 10.1371/Journal.Pone.0231599  0.345
2020 Criss SD, Palazzo L, Watson TR, Paquette AM, Sigel K, Wisnivesky J, Kong CY. Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden. Plos One. 15: e0228288. PMID 31995619 DOI: 10.1371/Journal.Pone.0228288  0.372
2020 Palazzo L, Sheehan D, Tramontano A, Kong CY. Abstract B087: Disparities and trends in genetic testing and erlotinib treatment among metastatic non-small cell lung cancer patients Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-B087  0.342
2019 Tramontano AC, Chen Y, Watson TR, Eckel A, Sheehan DF, Peters MLB, Pandharipande PV, Hur C, Kong CY. Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. Medicine. 98: e18082. PMID 31804317 DOI: 10.1097/Md.0000000000018082  0.312
2019 Criss SD, Cao P, Bastani M, Ten Haaf K, Chen Y, Sheehan DF, Blom EF, Toumazis I, Jeon J, de Koning HJ, Plevritis SK, Meza R, Kong CY. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study. Annals of Internal Medicine. PMID 31683314 DOI: 10.7326/M19-0322  0.386
2019 Ten Haaf K, Bastani M, Cao P, Jeon J, Toumazis I, Han SS, Plevritis SK, Blom EF, Kong CY, Tammemägi MC, Feuer EJ, Meza R, de Koning HJ. A comparative modeling analysis of risk-based lung cancer screening strategies. Journal of the National Cancer Institute. PMID 31566216 DOI: 10.1093/Jnci/Djz164  0.379
2019 Hammer MM, Palazzo LL, Kong CY, Hunsaker AR. Cancer Risk in Subsolid Nodules in the National Lung Screening Trial Radiology. 293: 441-448. PMID 31526256 DOI: 10.1148/Radiol.2019190905  0.345
2019 Chen Y, Criss SD, Watson TR, Eckel A, Palazzo L, Tramontano AC, Wang Y, Mercaldo ND, Kong CY. Cost and Utilization of Lung Cancer End-of-Life Care Among Racial-Ethnic Minority Groups in the United States. The Oncologist. PMID 31501272 DOI: 10.1634/Theoncologist.2019-0303  0.356
2019 Chen Y, Watson TR, Criss SD, Eckel A, Palazzo L, Sheehan DF, Kong CY. A simulation study of the effect of lung cancer screening in China, Japan, Singapore, and South Korea. Plos One. 14: e0220610. PMID 31361789 DOI: 10.1371/Journal.Pone.0220610  0.407
2019 Tramontano AC, Chen Y, Watson TR, Eckel A, Hur C, Kong CY. Esophageal cancer treatment costs by phase of care and treatment modality, 2000-2013. Cancer Medicine. PMID 31347306 DOI: 10.1002/Cam4.2451  0.341
2019 Rose J, Homa L, Kong CY, Cooper GS, Kattan MW, Ermlich BO, Meyers JP, Primrose JN, Pugh SA, Shinkins B, Kim U, Meropol NJ. Development and validation of a model to predict outcomes of colon cancer surveillance. Cancer Causes & Control : Ccc. PMID 31129907 DOI: 10.1007/S10552-019-01187-X  0.355
2019 Criss SD, Mooradian MJ, Kong CY. Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer-In Reply. Jama Oncology. PMID 31095247 DOI: 10.1001/Jamaoncol.2019.1100  0.372
2019 Sigel KM, Stone K, Wisnivesky JP, Park LS, Kong CY, Silverberg MJ, Brown S, Goetz M, Rodriguez-Barradas MC, Gibert C, Shebl F, Bedimo R, Wadia R, King J, Crothers K. Short-term outcomes for lung cancer resection surgery in HIV infection. Aids (London, England). PMID 30889013 DOI: 10.1097/Qad.0000000000002200  0.339
2019 Palazzo LL, Sheehan DF, Tramontano AC, Kong CY. Disparities and Trends in Rates of Genetic Testing and Erlotinib Treatment Among Metastatic Non-Small Cell Lung Cancer Patients. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 30787053 DOI: 10.1158/1055-9965.Epi-18-0917  0.349
2019 Yong PC, Sigel K, de-Torres JP, Mhango G, Kale M, Kong CY, Zulueta JJ, Wilson D, Brown SW, Slatore C, Wisnivesky J. The effect of radiographic emphysema in assessing lung cancer risk. Thorax. PMID 30723183 DOI: 10.1136/Thoraxjnl-2018-212457  0.38
2018 Sheehan DF, Criss SD, Chen Y, Eckel A, Palazzo L, Tramontano AC, Hur C, Cipriano LE, Kong CY. Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare. Cancer Medicine. PMID 30575329 DOI: 10.1002/Cam4.1896  0.36
2018 Choi JG, Nipp RD, Tramontano A, Ali A, Zhan T, Pandharipande P, Dowling EC, Ferrone CR, Hong TS, Schrag D, Fernandez-Del Castillo C, Ryan DP, Kong CY, Hur C. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. The Oncologist. PMID 30559125 DOI: 10.1634/Theoncologist.2018-0114  0.308
2018 Criss SD, Mooradian MJ, Sheehan DF, Zubiri L, Lumish MA, Gainor JF, Reynolds KL, Kong CY. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. Jama Oncology. PMID 30543349 DOI: 10.1001/Jamaoncol.2018.5449  0.374
2018 Jeon J, Holford TR, Levy DT, Feuer EJ, Cao P, Tam J, Clarke L, Clarke J, Kong CY, Meza R. Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. Annals of Internal Medicine. PMID 30304504 DOI: 10.7326/M18-1250  0.321
2018 Peters MLB, Eckel A, Mueller PP, Tramontano AC, Weaver DT, Lietz A, Hur C, Kong CY, Pandharipande PV. Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model. Pancreatology : Official Journal of the International Association of Pancreatology (Iap) ... [Et Al.]. PMID 30143405 DOI: 10.1016/J.Pan.2018.07.009  0.31
2018 Tramontano AC, Nipp R, Mercaldo ND, Kong CY, Schrag D, Hur C. Survival Disparities by Race and Ethnicity in Early Esophageal Cancer. Digestive Diseases and Sciences. PMID 30109578 DOI: 10.1007/S10620-018-5238-6  0.332
2018 Kong CY, Sigel K, Criss SD, Sheehan DF, Triplette M, Silverberg MJ, Henschke CI, Justice A, Braithwaite RS, Wisnivesky J, Crothers K. Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ ≥ 500: a simulation study. Aids (London, England). PMID 29683843 DOI: 10.1097/Qad.0000000000001818  0.365
2018 Criss SD, Sheehan DF, Palazzo L, Kong CY. Population impact of lung cancer screening in the United States: Projections from a microsimulation model. Plos Medicine. 15: e1002506. PMID 29415013 DOI: 10.1371/Journal.Pmed.1002506  0.396
2018 Ostvar S, Choi JG, Chu JN, Dougan ML, Gainor JF, Reynolds KL, Nipp RD, Kong CY, Hur C. Cost-effectiveness of immune checkpoint inhibition in metastatic gastric and esophageal tumors. Journal of Clinical Oncology. 36: 56-56. DOI: 10.1200/Jco.2018.36.4_Suppl.56  0.311
2018 Chen Y, Criss S, Sheehan D, Kong C. A Simulation Study of the Effect of Screening on Lung Cancer Mortality in Asia Value in Health. 21. DOI: 10.1016/J.Jval.2018.07.172  0.397
2018 Criss S, Mooradian M, Lumish M, Reynolds K, Kong C. Cost-Effectiveness of Durvalumab after Chemoradiation in Stage III Non-Small Cell Lung Cancer (Nsclc) Value in Health. 21. DOI: 10.1016/J.Jval.2018.07.090  0.361
2018 Jeon J, Holford T, Levy D, Feuer E, Cao P, Tam J, Clarke L, Clarke J, Kong C, Meza R. OA09.05 Potential Reduction in Lung Cancer Mortality in the US from 2015-2065: A Comparative Modeling Approach Journal of Thoracic Oncology. 13: S341-S342. DOI: 10.1016/J.Jtho.2018.08.284  0.363
2017 Reddy KP, Kong CY, Hyle EP, Baggett TP, Huang M, Parker RA, Paltiel AD, Losina E, Weinstein MC, Freedberg KA, Walensky RP. Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. Jama Internal Medicine. PMID 28975270 DOI: 10.1001/Jamainternmed.2017.4349  0.315
2017 Lubitz C, Ali A, Zhan T, Heberle C, White C, Ito Y, Miyauchi A, Gazelle GS, Kong CY, Hur C. The thyroid cancer policy model: A mathematical simulation model of papillary thyroid carcinoma in The U.S. population. Plos One. 12: e0177068. PMID 28481909 DOI: 10.1371/Journal.Pone.0177068  0.347
2017 Triplette M, Sigel KM, Morris A, Shahrir S, Wisnivesky JP, Kong CY, Diaz PT, Petraglia A, Crothers K. Emphysema and soluble CD14 are associated with pulmonary nodules in HIV-infected patients: Implications for lung cancer screening. Aids (London, England). PMID 28463881 DOI: 10.1097/Qad.0000000000001529  0.319
2017 Ten Haaf K, Jeon J, Tammemägi MC, Han SS, Kong CY, Plevritis SK, Feuer EJ, de Koning HJ, Steyerberg EW, Meza R. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. Plos Medicine. 14: e1002277. PMID 28376113 DOI: 10.1371/Journal.Pmed.1002277  0.356
2017 Sheehan DF, Criss SD, Gazelle GS, Pandharipande PV, Kong CY. Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach. Plos One. 12: e0173119. PMID 28273181 DOI: 10.1371/Journal.Pone.0173119  0.401
2017 Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, Rubenstein JH, Tramontano AC, Dowling EC, Hazelton WD, Luebeck EG, Lansdorp-Vogelaar I, Hur C. Cost-Effectiveness of Screening Patients with Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 28238953 DOI: 10.1016/J.Cgh.2017.02.017  0.365
2017 Han SS, Ten Haaf K, Hazelton WD, Munshi VN, Jeon J, Erdogan SA, Johanson C, McMahon PM, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK. The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. International Journal of Cancer. PMID 28073150 DOI: 10.1002/Ijc.30602  0.36
2017 Tramontano A, Nipp RD, Kong CY, Pandharipande P, Dowling E, Schrag D, Hur C. Disparities in cancer outcomes across age, sex, and race/ethnicity among pancreatic cancer patients. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E18071  0.307
2017 Choi J, Nipp RD, Tramontano A, Ali A, Zhan T, Kong CY, Pandharipande P, Dowling E, Ferrone C, Hong TS, Schrag D, Castillo CF, Ryan DP, Hur C. Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: Results of a decision analysis. Journal of Clinical Oncology. 35: 4117-4117. DOI: 10.1200/Jco.2017.35.15_Suppl.4117  0.301
2016 Tramontano AC, Sheehan DF, McMahon PM, Dowling EC, Holford TR, Ryczak K, Lesko SM, Levy DT, Kong CY. Evaluating the impacts of screening and smoking cessation programmes on lung cancer in a high-burden region of the USA: a simulation modelling study. Bmj Open. 6: e010227. PMID 26928026 DOI: 10.1136/Bmjopen-2015-010227  0.381
2016 Rose J, Homa L, Kong CY, Cooper GS, Kattan MW, Meropol NJ. Predicted benefit of alternative post-treatment surveillance strategies in stage II and III colon cancer survivors. Journal of Clinical Oncology. 34: 3623-3623. DOI: 10.1200/Jco.2016.34.15_Suppl.3623  0.329
2015 Pandharipande PV, Jeon A, Heberle CR, Dowling EC, Kong CY, Chung DC, Brugge WR, Hur C. Screening for Pancreatic Adenocarcinoma in BRCA2 Mutation Carriers: Results of a Disease Simulation Model. Ebiomedicine. 2: 1980-6. PMID 26844277 DOI: 10.1016/J.Ebiom.2015.11.005  0.344
2015 Hur C, Tramontano AC, Dowling EC, Brooks GA, Jeon A, Brugge WR, Gazelle GS, Kong CY, Pandharipande PV. Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size: Positive Implications for Future Targeted Screening. Pancreas. PMID 26692444 DOI: 10.1097/Mpa.0000000000000587  0.301
2015 Lowry KP, Turan EA, Eisenberg J, Kong CY, Barnes JA, Pandharipande PV. Projected Effects of Radiation-Induced Cancers on Life Expectancy in Patients Undergoing CT Surveillance for Limited-Stage Hodgkin Lymphoma: A Markov Model. Ajr. American Journal of Roentgenology. 204: 1228-33. PMID 26001232 DOI: 10.2214/Ajr.14.13287  0.33
2015 Hur C, Choi SE, Kong CY, Wang GQ, Xu H, Polydorides AD, Xue LY, Perzan KE, Tramontano AC, Richards-Kortum RR, Anandasabapathy S. High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis. World Journal of Gastroenterology : Wjg. 21: 5513-23. PMID 25987774 DOI: 10.3748/Wjg.V21.I18.5513  0.335
2015 Lowry KP, Gazelle GS, Gilmore ME, Johanson C, Munshi V, Choi SE, Tramontano AC, Kong CY, McMahon PM. Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis. Cancer. 121: 1556-62. PMID 25652107 DOI: 10.1002/Cncr.29225  0.389
2015 Swan JS, Kong CY, Hur C, Halpern EF, Itauma O, Williams O, Motazedi T, Lee JM. Comparing morbidities of testing with a new index: screening colonoscopy versus core-needle breast biopsy. Journal of the American College of Radiology : Jacr. 12: 295-301. PMID 25441485 DOI: 10.1016/J.Jacr.2014.08.014  0.308
2015 Pandharipande PV, Heberle C, Dowling EC, Kong CY, Tramontano A, Perzan KE, Brugge W, Hur C. Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Radiology. 275: 177-87. PMID 25393849 DOI: 10.1148/Radiol.14141282  0.346
2014 Kang SK, Turan EA, Eisenberg JD, Lee PA, Kong CY, Pandharipande PV. Microsimulation model of CT versus MRI surveillance of Bosniak IIF renal cystic lesions: should effects of radiation exposure affect selection of imaging strategy? Ajr. American Journal of Roentgenology. 203: W629-36. PMID 25415728 DOI: 10.2214/Ajr.14.12550  0.318
2014 McMahon PM, Meza R, Plevritis SK, Black WC, Tammemagi CM, Erdogan A, ten Haaf K, Hazelton W, Holford TR, Jeon J, Clarke L, Kong CY, Choi SE, Munshi VN, Han SS, et al. Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling. Plos One. 9: e99978. PMID 24979231 DOI: 10.1371/Journal.Pone.0099978  0.391
2014 Rose J, Augestad KM, Kong CY, Meropol NJ, Kattan MW, Hong Q, An X, Cooper GS. A simulation model of colorectal cancer surveillance and recurrence. Bmc Medical Informatics and Decision Making. 14: 29. PMID 24708517 DOI: 10.1186/1472-6947-14-29  0.347
2014 Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, Choi SE, Jeon J, Han SS, Munshi V, van Rosmalen J, Pinsky P, McMahon PM, de Koning HJ, Feuer EJ, et al. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer. 120: 1713-24. PMID 24577803 DOI: 10.1002/Cncr.28623  0.397
2014 Lubitz CC, Kong CY, McMahon PM, Daniels GH, Chen Y, Economopoulos KP, Gazelle GS, Weinstein MC. Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer. 120: 1345-52. PMID 24481684 DOI: 10.1002/Cncr.28562  0.331
2014 de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, Erdogan SA, Kong CY, Han SS, van Rosmalen J, Choi SE, Pinsky PF, Berrington de Gonzalez A, Berg CD, Black WC, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 160: 311-20. PMID 24379002 DOI: 10.7326/M13-2316  0.424
2013 Tramontano AC, Cipriano LE, Kong CY, Shepard JA, Lanuti M, Gazelle GS, McMahon PM. Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer. Ajr. American Journal of Roentgenology. 200: 1020-7. PMID 23617484 DOI: 10.2214/Ajr.12.8968  0.344
2013 Pandharipande PV, Eisenberg JD, Lee RJ, Gilmore ME, Turan EA, Singh S, Kalra MK, Liu B, Kong CY, Gazelle GS. Patients with testicular cancer undergoing CT surveillance demonstrate a pitfall of radiation-induced cancer risk estimates: the timing paradox. Radiology. 266: 896-904. PMID 23249573 DOI: 10.1148/Radiol.12121015  0.347
2012 McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Tramontano AC, Cipriano LE, Bouzan C, Gazelle GS. Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Analysis : An Official Publication of the Society For Risk Analysis. 32: S117-24. PMID 22882882 DOI: 10.1111/J.1539-6924.2011.01652.X  0.409
2012 Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology. 143: 567-75. PMID 22626608 DOI: 10.1053/J.Gastro.2012.05.010  0.322
2012 Moolgavkar SH, Holford TR, Levy DT, Kong CY, Foy M, Clarke L, Jeon J, Hazelton WD, Meza R, Schultz F, McCarthy W, Boer R, Gorlova O, Gazelle GS, Kimmel M, et al. Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. Journal of the National Cancer Institute. 104: 541-8. PMID 22423009 DOI: 10.1093/Jnci/Djs136  0.356
2012 Kong CY, Lee JM, McMahon PM, Lowry KP, Omer ZB, Eisenberg JD, Pandharipande PV, Gazelle GS. Using radiation risk models in cancer screening simulations: important assumptions and effects on outcome projections. Radiology. 262: 977-84. PMID 22357897 DOI: 10.1148/Radiol.11110352  0.361
2012 Lowry KP, Lee JM, Kong CY, McMahon PM, Gilmore ME, Cott Chubiz JE, Pisano ED, Gatsonis C, Ryan PD, Ozanne EM, Gazelle GS. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. Cancer. 118: 2021-30. PMID 21935911 DOI: 10.1002/Cncr.26424  0.301
2011 McMahon PM, Kong CY, Bouzan C, Weinstein MC, Cipriano LE, Tramontano AC, Johnson BE, Weeks JC, Gazelle GS. Cost-effectiveness of computed tomography screening for lung cancer in the United States. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1841-8. PMID 21892105 DOI: 10.1097/Jto.0B013E31822E59B3  0.396
2010 Hayeck TJ, Kong CY, Spechler SJ, Gazelle GS, Hur C. The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data. Diseases of the Esophagus : Official Journal of the International Society For Diseases of the Esophagus / I.S.D.E. 23: 451-7. PMID 20353441 DOI: 10.1111/J.1442-2050.2010.01054.X  0.343
2010 Prosser LA, Kong CY, Rusinak D, Waisbren SL. Projected costs, risks, and benefits of expanded newborn screening for MCADD. Pediatrics. 125: e286-94. PMID 20123779 DOI: 10.1542/Peds.2009-0605  0.319
2009 Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS. Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics. 27: 533-45. PMID 19663525 DOI: 10.2165/11314830-000000000-00000  0.317
2009 Hur C, Broughton DE, Kong CY, Ozanne EM, Richards EB, Truong T, Gazelle GS. Patient preferences for the chemoprevention of colorectal cancer. Digestive Diseases and Sciences. 54: 2207-14. PMID 19057995 DOI: 10.1007/S10620-008-0609-Z  0.311
2008 McMahon PM, Kong CY, Weinstein MC, Tramontano AC, Cipriano LE, Johnson BE, Weeks JC, Gazelle GS. Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer. 113: 3440-9. PMID 18988293 DOI: 10.1002/Cncr.23962  0.386
2008 McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Kuntz KM, Shepard JA, Swensen SJ, Gazelle GS. Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology. 248: 278-87. PMID 18458247 DOI: 10.1148/Radiol.2481071446  0.37
2006 Muthukumar M, Kong CY. Simulation of polymer translocation through protein channels. Proceedings of the National Academy of Sciences of the United States of America. 103: 5273-8. PMID 16567657 DOI: 10.1073/Pnas.0510725103  0.471
2005 Kong CY, Muthukumar M. Simulations of stochastic sensing of proteins. Journal of the American Chemical Society. 127: 18252-61. PMID 16366579 DOI: 10.1021/Ja055695O  0.459
2004 Kong CY, Muthukumar M. Polymer translocation through a nanopore. II. Excluded volume effect. The Journal of Chemical Physics. 120: 3460-6. PMID 15268503 DOI: 10.1063/1.1642588  0.457
2002 Kong CY, Muthukumar M. Modeling of polynucleotide translocation through protein pores and nanotubes. Electrophoresis. 23: 2697-703. PMID 12210174 DOI: 10.1002/1522-2683(200208)23:16<2697::Aid-Elps2697>3.0.Co;2-M  0.464
2002 McNamara J, Kong CY, Muthukumar M. Monte Carlo studies of adsorption of a sequenced polyelectrolyte to patterned surfaces Journal of Chemical Physics. 117: 5354-5360. DOI: 10.1063/1.1501125  0.462
2000 Ellis M, Kong CY, Muthukumar M. Polyelectrolyte adsorption on heterogeneously charged surfaces Journal of Chemical Physics. 112: 8723-8729. DOI: 10.1063/1.481474  0.449
1998 Kong CY, Muthukumar M. Monte Carlo study of adsorption of a polyelectrolyte onto charged surfaces Journal of Chemical Physics. 109: 1522-1527. DOI: 10.1063/1.476703  0.473
Show low-probability matches.